GlassScriptPhysician profile
Nicholas J Mayer
NPI 1104075597
$2,482.31
in general payments reported to CMS, 2019-2025
23 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $252 · 2021: $148 · 2022: $101 · 2023: $185 · 2024: $905 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639 · Education: $9.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.22 |
| Education | $9.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $374.10 | 2020-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $314.75 | 2023-2024 | Velphoro, Liberty Select Cycler, Nxstage System One |
| Novo Nordisk INC | $307.59 | 2019-2021 | |
| Nxstage Medical, INC. | $247.34 | 2019-2024 | |
| Amgen INC. | $159.00 | 2019-2024 | Krystexxa, Tavneos, Aranesp |
| Abbvie INC. | $149.64 | 2023-2025 | |
| Travere Therapeutics, INC. | $134.59 | 2024-2025 | Filspari |
| Vifor Pharma, INC. | $134.42 | 2019-2025 | Veltassa |
| Phathom Pharmaceuticals, INC. | $125.27 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Arexvy |
| Mallinckrodt Enterprises LLC | $76.99 | 2019 | |
| Calliditas Therapeutics US INC. | $65.17 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $50.42 | 2020-2025 | Rayaldee |
| Cormedix INC. | $35.95 | 2024 | Defencath |
| Lilly USA, LLC | $28.83 | 2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.58 | 2021 | |
| Akebia Therapeutics INC | $22.62 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.07 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.67 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $19.17 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.09 | 2019 | |
| Ardelyx, INC. | $14.20 | 2024 | Ibsrela |
| Allergan, INC. | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.